While immunotherapy has already revolutionized the treatment of blood cancers, “solid” tumors—like those found in the brain, lungs, or bones—have remained notoriously difficult to treat. That changed this month with the launch of a pioneering global trial from the NexTGen team, which has successfully dosed the first young adult patient with a new form of CAR-T cell therapy.
This “Next-Gen” therapy works by taking a patient’s own T-cells and genetically engineering them to recognize a specific protein called B7-H3, which is found on the surface of most solid tumors. Unlike previous versions of the treatment, these engineered cells are designed to survive the harsh “microenvironment” inside a solid tumor, which normally shuts down the immune system’s defenses.
What makes this trial particularly significant is its focus on teenagers and young adults, a demographic that has historically seen slower improvements in cancer survival rates compared to children or older adults. If successful, this “molecular shredder” approach could provide a gentler, more effective alternative to traditional chemotherapy, offering new hope for those battling the most aggressive forms of solid-tissue cancers.
